Treatment and outcomes of limited stage small cell lung cancer in the Canadian small cell lung cancer database (CASCADE) [0.03%]
加拿大小细胞肺癌数据库（CASCADE）中局限期小细胞肺癌的治疗及预后情况分析
William J Phillips,Luna Jia Zhan,Deepro Chowdhury et al.
William J Phillips et al.
Introduction: There have been minimal advances in the systemic treatment of limited stage small cell lung cancer (LS-SCLC) for decades. With the publication of the ADRIATIC trial, consolidation durvalumab is a new standar...
First-line treatment in EGFR-mutated non-small cell lung cancer: brief report of an individual patient data comparison of phase 3 clinical trials [0.03%]
表皮生长因子受体突变的非小细胞肺癌一线治疗：III期临床试验患者数据对比个案报告
Andrea Torchia,Arianna Sabatini,Elisabetta Bengala et al.
Andrea Torchia et al.
Introduction: Clinical trials evaluated the efficacy and safety of novel first-line treatment strategies for advanced epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC), relative to osimert...
Long-term outcomes of Extensive-Stage small cell lung cancer treated with chemotherapy or Chemo-immunotherapy: A propensity score adjusted cohort study [0.03%]
广泛期小细胞肺癌化疗或免疫化疗长期疗效的队列研究：倾向性评分匹配分析
Heya Batah,Emily C Zabor,Bridget Adcock et al.
Heya Batah et al.
Background: Combining atezolizumab with carboplatin plus etoposide (Carbo-E) improved overall survival (OS) in patients with extensive-stage small cell lung cancer (ES-SCLC). However, there is a paucity of real-world outc...
Tumor heterogeneity involving SCLC with a single exon deletion in RB1 and adenocarcinoma with EGFR-L718V mutation in EGFR-TKI-resistant lung cancer [0.03%]
耐药性肺癌肿瘤异质性涉及RB1单一外显子缺失的SCLC和EGFR具有EGFR-TKI突变的肺腺癌
Sho Kakuto,Ken Uchibori,Yuri Yamamoto et al.
Sho Kakuto et al.
Introduction: EGFR tyrosine kinase inhibitors (EGFR-TKIs) have significantly improved the outcomes of EGFR-mutant non-small cell lung cancer (NSCLC); however, resistance commonly develops. While secondary EGFR mutations (...
Tarlatamab population survival kinetics in extensive-stage small cell lung cancer: brief report [0.03%]
关于大范围小细胞肺癌患者使用tarlatamab后的生存动力学的简短报告
David J Stewart,Bingnan Zhang,Razelle Kurzrock
David J Stewart
Purpose: Immune checkpoint inhibitors (ICIs) prolong progression-free survival (PFS) and overall survival (OS) in extensive-stage small cell lung cancer (ES-SCLC). ES-SCLC PFS curve exponential decay nonlinear regression ...
Genetic composition and evolutionary trajectories of brain metastasis in non-small-cell lung cancer [0.03%]
非小细胞肺癌脑转移的基因组成和进化轨迹
Marcin Nicoś,Natalia Galant,Anna Kowalczyk et al.
Marcin Nicoś et al.
Introduction: Non-small cell lung cancer (NSCLC) is an aggressive solid malignancy that commonly disseminates to the central nervous system (CNS). Comparative analysis of primary NSCLC and brain metastases (BM) by next-ge...
Impact of N1 lymph node burden on survival outcomes in non-skip pN2 non-small-cell lung cancer [0.03%]
N1淋巴结负荷对非跳过pN2期非小细胞肺癌生存结局的影响
Bin Luo,Shenhua Liang,Leqi Zhong et al.
Bin Luo et al.
Objectives: This study aimed to evaluate the prognostic value of quantitative N1 nodal burden metrics-including positive node count, positive station count, lymph node ratio (LNR), and lymph node station ratio (LNsR)-in p...
NHWD-870 suppresses tumor proliferation via the BRD4/STRADA/CCND1 axis in small cell lung cancer [0.03%]
NHWD-870通过BRD4/STRADA/CCND1轴抑制小细胞肺癌的增殖
Linrui Ma,Xiangyu Zhang,Shidong Xu et al.
Linrui Ma et al.
Background: Small cell lung cancer (SCLC) is a highly aggressive malignancy with poor prognosis and limited therapeutic options. The lack of effective targeted therapies for SCLC is a major limitation of this field. Bromo...
Prevalence and molecular landscape of NRG1 fusions in Japanese solid tumors: a nationwide data analysis using the C-CAT database [0.03%]
日本实体肿瘤NRG1融合的患病率和分子特征全国数据分析：基于C-CAT数据库的研究
Masaki Ishida,Tadaaki Yamada,Ryo Tsunashima et al.
Masaki Ishida et al.
Introduction: Neuregulin 1 (NRG1) gene fusions are critical oncogenic drivers that activate the ERBB signaling pathway across various solid tumors. Although targeted therapies for NRG1 fusion-positive cancers are advancin...